Laquinimod Phase IIa Study in Active Crohn's Disease
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00737932
- Locations
- 🇧🇪
Teva Investigational Site 3711, Bonheiden, Belgium
🇧🇪Teva Investigational Site 3712, Leuven, Belgium
🇧🇪Teva Investigational Site 3713, Roeselare, Belgium
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT00724048
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, San Diego, California, United States
🇺🇸Colorado Neurological Institute, Littleton, Colorado, United States
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 559
- Registration Number
- NCT00696332
- Locations
- 🇺🇸
CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center, San Francisco, California, United States
🇺🇸University of Kansas Medical Center - Dept of Neurology, Kansas City, Kansas, United States
🇺🇸Johns Hopkins OPC - Meyer Bldg, Baltimore, Maryland, United States
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 481
- Registration Number
- NCT00666224
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 437
- Registration Number
- NCT00665223
- Locations
- 🇦🇹
LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz, Graz, Styria, Austria
🇦🇹Innsbruck Medical University, Anichstraße 35, Innsbruck, Tyrol, Austria
🇧🇪University Hospital Gasthuisberg, Leuven, Flemish Brabant, Belgium
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1331
- Registration Number
- NCT00605215
- Locations
- 🇺🇸
Teva Investigational Site 1267, Birmingham, Alabama, United States
🇺🇸Teva Investigational Site 1237, Phoenix, Arizona, United States
🇺🇸Teva Investigational Site 1252, Phoenix, Arizona, United States
Albuterol HFA MDI in Pediatric Participants With Asthma
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00577655
- Locations
- 🇺🇸
Pediatric Care Medical Group, Inc., Huntington Beach, California, United States
🇺🇸California Allergy & Asthma Medical Group, Palmdale, California, United States
🇺🇸Center for Clinical Trials, LLC, Paramount, California, United States
A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021
- Conditions
- Healthy
- Interventions
- Drug: DR-1021Drug: Mircette®Drug: Kariva®
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00544882
- Locations
- 🇺🇸
Duramed Investigational Site, Seattle, Washington, United States
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
- Conditions
- Asthma
- Interventions
- Drug: Albuterol-HFA-BAIDrug: Albuterol-HFA-MDI
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00530062
- Locations
- 🇺🇸
Clinical Study Site, Lake Oswego, Oregon, United States
🇺🇸Teva Clinical Study Site, Lakewood, Colorado, United States
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1106
- Registration Number
- NCT00509145
- Locations
- 🇺🇸
Teva Investigational Site 1076, Phoenix, Arizona, United States
🇺🇸Teva Investigational Site 1090, Centennial, Colorado, United States
🇺🇸Teva Investigational Site 1088, Fort Collins, Colorado, United States